Matinas BioPharma’s LNC Technology Promises Safer Chemotherapy

The latest update is out from Matinas BioPharma (MTNB).

Matinas BioPharma Holdings, Inc. reported promising outcomes from a study where healthy mice received their innovative oral lipid nanocrystal (LNC) formulation of the chemotherapy drug docetaxel. This new delivery method significantly reduced the drug’s toxicity, normally seen with intravenous delivery, as evidenced by maintained body weight in treated mice compared to weight loss in the control group. The LNC technology not only minimizes free circulating drug levels but also targets tumor cells more effectively. These findings could lead to better treatment options for cancer patients, and the company aims to further explore this approach in various tumor types and other potent chemotherapies.

Find detailed analytics on MTNB stock on TipRanks’ Stock Analysis page.